The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Forecasted Rise In Market Size Of The Mammalian Cell Banking Market During The Forecast Period?
The mammalian cell banking market has experienced rapid growth in its size in recent years. It is projected to expand from $3.14 billion in 2025 to $3.5 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.3%. Historically, this expansion has been attributable to developments in monoclonal antibodies, an increase in vaccine manufacturing, regulatory quality requirements, the broadening of academic research, and the commercialization of biologics.
The mammalian cell banking market size is projected to undergo significant expansion in the coming years, with its value set to reach $5.31 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.0%. This anticipated growth over the forecast period is primarily driven by advancements in gene therapy, the increasing prevalence of personalized medicine, ongoing biosimilar development, the expansion of cell-based therapy pipelines, and the necessity for long-term cell traceability. Prominent trends expected during this period include the standardization of cell line preservation, the growth of biopharmaceutical pipelines, the establishment of more CGMP-compliant cell banks, a heightened focus on genetic stability, and an increase in outsourcing to specialized facilities.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28262&type=smp
What Major Growth Factors Are Impacting The Mammalian Cell Banking Market?
The increasing requirement for cell-based therapies is anticipated to boost the expansion of the mammalian cell banking market in the future. Cell-based therapies involve cutting-edge medical approaches that utilize living cells, frequently altered or engineered, to mend, substitute, or restore damaged tissues and organs, delivering precise solutions for a broad spectrum of illnesses. The need for cell-based therapies is escalating due to the rising occurrence of chronic and rare diseases, which generates an urgent necessity for more potent and targeted treatment options. Mammalian cell banking assists cell-based therapies by supplying a dependable, uniform source of top-quality cells, guaranteeing uniformity, safety, and expandability in the creation and production of regenerative treatments. For example, in April 2024, the American Society of Gene and Cell Therapy, a US non-profit medical and scientific body, stated that the quantity of therapies across all clinical pipeline stages has expanded since the close of 2023, with Phase I exhibiting the strongest growth of 11% compared to before the fourth quarter of 2022. Consequently, the increasing need for cell-based therapies is propelling the growth of the mammalian cell banking market.
Which Segment-Based Categories Are Covered In The Mammalian Cell Banking Market?
The mammalian cell banking market covered in this report is segmented –
1) By Product Type: Master Cell Bank, Working Cell Bank
2) By Cell Type: Chinese Hamster Ovary Mammalian Cell Banking (CHO), Baby Hamster Kidney (BHK), Non-Secreting 0 (NS0), YB2/0 And P2/0, Human Embryonic Kidney 293 (HEK293) And Derivatives, Henrietta Lacks (HELA)
3) By Storage Type: Liquid Nitrogen, Controlled Rate Freezer, Flash Freezing
4) By Application: Drug Development, Vaccine Production, Gene Therapy, Monoclonal Antibody Production
5) By End User: Academic And Research Laboratories, Biopharmaceutical Companies, Contract Research Organizations (CROs)
Subsegments:
1) By Master Cell Bank: Recombinant Cell Lines, Hybridoma Cell Lines, Primary Cell Lines, Genetically Engineered Cell Lines, Viral Vector Producing Cell Lines
2) By Working Cell Bank: Current Good Manufacturing Practice (CGMP)-Compliant Cell Banks, Research-Grade Cell Banks, Clinical Trial Cell Banks, Commercial Production Cell Banks, Stability Testing Cell Banks
Which Trends Are Guiding The Development Of The Mammalian Cell Banking Market?
Leading firms within the mammalian cell banking market are concentrating on creating novel solutions, including advanced stable cell line systems, with the aim of boosting cell line productivity, maintaining genetic stability over extended periods, and optimizing biopharmaceutical manufacturing workflows. These stable cell line systems comprise mammalian cells that have been genetically modified to reliably generate a specific protein or therapeutic agent across numerous generations, exhibiting significant genetic consistency and repeatability. As an example, in August 2024, WuXi Biologics, a biopharmaceutical enterprise from China, introduced the WuXia293 Stable platform, which is an inventive HEK293-based stable cell line system specifically crafted for the production and development of biological molecules that are challenging to express. Employing proprietary technology for mammalian cell line development, the platform guarantees consistent expression and uniform quality through extended cell passages. The WuXia293 Stable platform addresses issues of diminished yields and inferior quality typically encountered with conventional CHO cell systems by providing elevated protein titers, enhanced human-like glycosylation, and scalable production suitable for both clinical and commercial manufacturing.
Who Are The Prominent Players Across The Mammalian Cell Banking Market?
Major companies operating in the mammalian cell banking market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., Catalent Inc., Sartorius Stedim Biotech S A, Samsung Biologics Co Ltd, CMIC Holdings Co Ltd, WuXi Biologics Inc., Evotec SE, AGC Biologics Inc., GenScript ProBio Co Ltd, Syngene International Limited, KBI Biopharma Inc., Rentschler Biopharma SE, Polpharma Biologics S A, Abzena plc, 53Biologics, Cellistic, GBI Biomanufacturing, ABL Inc, OmniaBio, uBriGene Biosciences
Access The Complete Mammalian Cell Banking Market Report:
https://www.thebusinessresearchcompany.com/report/mammalian-cell-banking-global-market-report
Which Area Represents The Largest Portion Of The Mammalian Cell Banking Market?
North America was the largest region in the mammalian cell banking market in 2025. The regions covered in the mammalian cell banking market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Mammalian Cell Banking Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/report/mammalian-cell-banking-global-market-report
Browse Through More Reports Similar to the Global Mammalian Cell Banking Market 2026, By The Business Research Company
Cell Cultures Market Report 2026
https://www.thebusinessresearchcompany.com/report/cell-cultures-global-market-report
Cell Harvesting Market Report 2026
https://www.thebusinessresearchcompany.com/report/cell-harvesting-global-market-report
Cell Based Assays Market Report 2026
https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model